You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for budesonide; formoterol fumarate dihydrate and what is the scope of patent protection?

Budesonide; formoterol fumarate dihydrate is the generic ingredient in two branded drugs marketed by Mylan and Astrazeneca, and is included in two NDAs. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Budesonide; formoterol fumarate dihydrate has one hundred and sixty-two patent family members in thirty-nine countries.

Four suppliers are listed for this compound.

Summary for BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE
Recent Clinical Trials for BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Cipla Ltd.Phase 3
Actavis Inc.Phase 3
Teva Pharmaceuticals USAPhase 3

See all BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE clinical trials

Pharmacology for BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE
Paragraph IV (Patent) Challenges for BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
SYMBICORT Metered Inhalation budesonide; formoterol fumarate dihydrate 80 mcg/4.5 mcg per inhalation and 160 mcg/4.5 mcg per inhalation 021929 1 2018-06-26

US Patents and Regulatory Information for BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca SYMBICORT budesonide; formoterol fumarate dihydrate AEROSOL, METERED;INHALATION 021929-002 Jul 21, 2006 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Mylan BREYNA budesonide; formoterol fumarate dihydrate AEROSOL, METERED;INHALATION 211699-001 Mar 15, 2022 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Astrazeneca SYMBICORT budesonide; formoterol fumarate dihydrate AEROSOL, METERED;INHALATION 021929-002 Jul 21, 2006 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca SYMBICORT budesonide; formoterol fumarate dihydrate AEROSOL, METERED;INHALATION 021929-002 Jul 21, 2006 ⤷  Sign Up ⤷  Sign Up
Astrazeneca SYMBICORT budesonide; formoterol fumarate dihydrate AEROSOL, METERED;INHALATION 021929-002 Jul 21, 2006 ⤷  Sign Up ⤷  Sign Up
Astrazeneca SYMBICORT budesonide; formoterol fumarate dihydrate AEROSOL, METERED;INHALATION 021929-001 Jul 21, 2006 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Teva Pharma B.V.  Budesonide/Formoterol Teva Pharma B.V. budesonide, formoterol fumarate dihydrate EMEA/H/C/004882
Budesonide/Formoterol Teva Pharma B.V. is indicated in adults 18 years of age and older only.AsthmaBudesonide/Formoterol Teva Pharma B.V. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate:-in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists.or-in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.COPDSymptomatic treatment of patients with COPD with forced expiratory volume in 1 second (FEV1) 
Authorised no no no 2020-04-03
Teva Pharma B.V. Budesonide/Formoterol Teva Pharma B.V. budesonide, formoterol fumarate dihydrate EMEA/H/C/003953
Budesonide/Formoterol Teva Pharma B.V. is indicated in adults 18 years of age and older only.AsthmaBudesonide/Formoterol Teva Pharma B.V. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists.in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists. 
Withdrawn no no no 2014-11-19
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

Country Patent Number Title Estimated Expiration
Argentina 054295 DISPOSITIVO INHALADOR ⤷  Sign Up
Canada 2569923 DISPOSITIF D'INHALATION ET SON PROCEDE D'ASSEMBLAGE (AN INHALATION DEVICE AND A METHOD FOR ASSEMBLING SAID INHALATION DEVICE) ⤷  Sign Up
Poland 1768727 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0613371 SPC/GB02/033 United Kingdom ⤷  Sign Up PRODUCT NAME: FORMOTEROL (OPTIONALLY IN THE FORM OF THE FREE BASE OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, OR A SOLVATE OF SUCH FREE BASE OR SALT ESPECIALLY AS FORMOTEROL FUMARATE DIHYDRATE) AND BUDESONIDE; REGISTERED: SE SE16047, 16048 20000825; UK PL17901/0091 20010515; UK PL17901/0092 20010515
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.